Cargando…
Nanomedicine-Based Therapeutics to Combat Acute Lung Injury
Acute lung injury (ALI) or its aggravated stage acute respiratory distress syndrome (ARDS) may lead to a life-threatening form of respiratory failure, resulting in high mortality of up to 30–40% in most studies. Although there have been decades of research since ALI was first described in 1967, the...
Autores principales: | Bian, Shuai, Cai, Hongfei, Cui, Youbin, Liu, Wanguo, Xiao, Chunsheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7987274/ https://www.ncbi.nlm.nih.gov/pubmed/33776431 http://dx.doi.org/10.2147/IJN.S300594 |
Ejemplares similares
-
Localized delivery of nanomedicine and antibodies for combating COVID-19
por: Tu, Bin, et al.
Publicado: (2023) -
Nanomedicine for Treatment of Acute Lung Injury and Acute Respiratory Distress Syndrome
por: Sadikot, Ruxana T., et al.
Publicado: (2017) -
Combating atherosclerosis with targeted nanomedicines: recent advances and future prospective
por: Nakhlband, Ailar, et al.
Publicado: (2018) -
Peptide Nanomedicines for Treatment of Acute Lung Injury
por: Sadikot, Ruxana T.
Publicado: (2012) -
Polymeric nanomedicines for the treatment of hepatic diseases
por: Luo, Feixiang, et al.
Publicado: (2022)